AiCure
AiCure provides a clinical trial management platform with patient-level AI, supporting traditional, decentralized, and hybrid trials. Founded in 2010, it operates in over 41 countries and offers solutions like AiCure Patient Connect, AiCure Platform, and Clinical Site Services.
Services
AiCure provides a comprehensive clinical trial management platform that leverages patient-level AI technology. The company offers tailored solutions such as AiCure Patient Connect, AiCure Platform, and Clinical Site Services. These services support a variety of trial types, including traditional site-based trials, decentralized virtual trials, and hybrid trials. Additionally, AiCure operates an open-source platform, OpenDBM, which allows the scientific community to access and apply a wide range of digital biomarker algorithms. Their Clinical Site Services are specifically designed to reduce the clinical technology burden, thereby allowing healthcare professionals to focus more on patient care.
Products
AiCure offers several key products aimed at enhancing clinical trial management and patient compliance. The AiCure Platform is a central component, capturing and analyzing behavioral variables through digital biomarkers. The Patient Connect mobile app offers real-time dosing instructions and medication adherence support. Additionally, the company provides an array of resources, including blog posts, fact sheets, posters, publications, webinars, and videos to help users maximize the platform's potential. AiCure's portfolio also includes OpenDBM, an open-source platform for the application of digital biomarker algorithms.
Sector
AiCure operates within the clinical trial and medical technology sector. The company specializes in providing AI-driven solutions to improve clinical trial efficiency and patient outcomes. By focusing on innovations in digital biomarkers and medication adherence, AiCure contributes to advancing methods for data capture and analysis in clinical research. Their services and products are utilized across a global scale, operating in over 41 countries and supporting more than 45 languages. The adoption of both traditional and decentralized virtual trials positions AiCure at the forefront of evolving clinical trial methodologies.
History
Founded in 2010, AiCure has established itself as a significant player in the clinical trial technology industry. The company has secured multi-grant funding from the National Institutes of Health (NIH) to support its innovations. Over the years, AiCure has accumulated over 84 patents, highlighting its strong focus on research and development in digital biomarker algorithms. AiCure has captured over 1.1 million patient doses and supported more than 144 studies globally. Its commitment to advancing clinical trials through AI-driven solutions has enabled the company to grow and expand its footprint internationally.